




RealRate

PHARMACEUTICAL 2012

Array Biopharma INC
Rank 159 of 196



The relative strengths and weaknesses of Array Biopharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Array Biopharma INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 11% points. The greatest weakness of Array Biopharma INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 139% points.

The company's Economic Capital Ratio, given in the ranking table, is 95%, being 139% points below the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	70,562
Cost of Goods Sold	28,916
Intangible Assets	0
Liabilities, Current	69,808
Liabilities, Non-Current	150,424
Other Assets	3,114
Other Compr. Net Income	-5,525
Other Expenses	19,550
Other Liabilities	0
Other Net Income	0
Other Revenues	71,901
Property and Equipment	15,698
Research and Development	63,498
Selling, General and Administrative Expense	16,261

Output Variable	Value in 1000 USD
Assets	89,374
Liabilities	220,232
Expenses	128,225
Revenues	71,901
Stockholders Equity	-130,858
Net Income	-56,324
Comprehensive Net Income	-59,086
BaseVar	257,628
ECR before LimitedLiability	-222%
Economic Capital Ratio	95%